FEMSELECT
FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, and deployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel.
FEMSELECT
Industry:
Health Care Medical Medical Device Women's
Founded:
2012-01-01
Address:
Modi'in, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.femselect.com
Total Employee:
1+
Status:
Active
Contact:
1 215-940-8178
Email Addresses:
[email protected]
Total Funding:
3.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome
Similar Organizations
Ava
Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days.
G Medical Innovations
G Medical Innovations is a next-generation mobile health (mHealth) and e-health company.
Genetron Health
Genetron Health is a world-leading expert in precision medicine.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
Proactive For Her
Proactive For Her is a digital platform for women, offering accessible, personalized and confidential healthcare solutions.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Vezeeta
Vezeeta provides patients with a digital healthcare booking platform and management software.
Current Employees Featured
Founder
Investors List
Robin Hood Ventures
Robin Hood Ventures investment in Convertible Note - FEMSelect
Robin Hood Ventures
Robin Hood Ventures investment in Convertible Note - FEMSelect
Mid Atlantic Bio Angels
Mid Atlantic Bio Angels investment in Series A - FEMSelect
Official Site Inspections
http://www.femselect.com
- Host name: box5767.bluehost.com
- IP address: 162.241.253.51
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "FEMSelect"
FEMSelect - Crunchbase Company Profile & Funding
Organization. FEMSelect . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... FEMSelect is making a lasting impact on …See details»
Pelvic Floor Reconstructive Specialists - FEMSelect
Interest in the FEMSelect EnPlace system for minimally invasive approach to pelvic floor ligament fixation is growing quicky. EnPlace is now recognized as a “first line” approach for women with uterine or vaginal vault symptoms, …See details»
FEMSelect Company Profile | Management and Employees List
FEMSelect Profile and History FEMSelect specializes in EnPlace, a minimally invasive treatment for Pelvic Organ Prolapse, targeting women over 50 who experience discomfort related to this …See details»
Women's Health Leader FEMSelect Secures US$9M Series B …
Oct 19, 2022 FEMSelect is a women-led company with a mission to make a lasting impact on women's health by delivering innovative technologies that provide consistent results in a …See details»
FEMSelect 2025 Company Profile: Valuation, Funding & Investors
FEMSelect General Information Description. Developer of medical devices designed to treat pelvic organ prolapse disease in women. The company's devices offer a minimally-invasive …See details»
FEMSelect Company Profile - Office Locations, Competitors ... - Craft
FEMSelect is a healthcare company focusing on the treatment of pelvic organ prolapse (POP) condition. Its product, EnPlace, is a minimally-invasive POP treatment system that allows …See details»
Contact Us - FEMSelect
May 13, 2025 FEMSelect Ltd. HaMa’ayan 2 - First Floor. Modi’in, 7177871. Phone: +972-54-945-6260. Email: [email protected]See details»
FemSelect - VentureRadar
FEMSelect develops EnPlace®, a minimally invasive, meshless approach to pelvic floor ligament fixation. EnPlace is a truly minimally-invasive system conducted with no mesh and minimal …See details»
FEMSelect - The Org
FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. Industries. Consumer, Health Care + 1. Headquarters. Modi'in, Israel. Employees. 1 …See details»
FEMSelect Poised for Market Leadership with Strategic …
May 13, 2025 FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion. NEW YORK, …See details»
FEMSelect - F6S
Verified FEMSelect employees can claim the page to update it Similar companies FEM Inc Video Experience Platform: content recommendations, syndication, analytics FemTherapeutics Inc. …See details»
FEMSelect - Contacts, Employees, Board Members, Advisors
Organization. FEMSelect . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Board Member and Advisor Profiles 1. Contacts 3. …See details»
FEMSelect Launches Consumer Advocacy Campaign To Raise
Aug 3, 2023 FEMSelect is a women-led company with a mission to make a lasting impact on women's health by delivering innovative technologies that provide consistent results in a …See details»
Pelvic Prolapse Resources - FEMSelect
FEMSelect now introduces the revolutionary new system to provide Female Pelv ic Medicine and Re constructive Surgeons with an option for truly minimally invasive pelvic floor ligament …See details»
FEMSelect | Startup Profile and Investments - Bounce Watch
FEMSelect is an Israeli-based startup with a focus on health care.The company has developed EnPlace™, a minimally invasive and meshless system specifically designed for suturing …See details»
FEMSelect Addresses Pelvic Organ Prolapse — FemHealth Insights
Jun 20, 2024 FEMSelect’s EnPlace system is designed to be a mesh-free and dissection-free solution, providing a safe and effective approach to the treatment of pelvic organ prolapse …See details»
EnPlace® Technology - FEMSelect
May 13, 2025 EnPlace procedure takes approximately 30 minutes vs. commonly 75-120 minutes for the traditional, more invasive approach. The patented delivery system enables the precise …See details»
Meshless Device to be Considered for Pelvic Organ Prolapse
May 13, 2025 "I find most of my patients have so many options, but I can tailor the procedure to the patients’ goals. For example, if a patient comes in saying, ” I am young, I have prolapse …See details»
FEMSelect Poised for Market Leadership with Strategic
May 13, 2025 FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion. NEW YORK, …See details»
FEMSelect Breaks into U.S. Market with AcuityMD to Speed Market …
FEMSelect is leveraging AcuityMD’s platform to accelerate identification and engagement of U.S. physicians treating PFDs, which affect at least one in five women. In a 2022 study of more …See details»